Ask AI
ProCE Banner Activity

Évolution des thérapies ciblées pour le lymphome diffus à grandes cellules B récidivant/réfractaire (LDGCB)

PDF

Le paysage thérapeutique des patients atteints de LDGCB évolue rapidement, avec plusieurs thérapies ciblées en développement clinique. Dans ce commentaire, des experts abordent des questions clés concernant le rôle actuel de la gemcitabine associée à l'oxaliplatine dans le traitement du LDGCB récidivant/réfractaire, le potentiel curatif des thérapies par cellules CAR-T par rapport aux anticorps bispécifiques, ainsi que la sélection et la séquence des thérapies ciblées après progression sous thérapie par cellules CAR-T dans la prise en charge des patients atteints de LDGCB récidivant/réfractaire.

Released: August 17, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This program is intended for hematologists, oncologists, and other healthcare professionals who care for patients with DLBCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Educate colleagues and patients on the mechanisms of action and rationales for using novel targeted therapies in DLBCL

  • Evaluate the potential clinical application of emerging evidence for novel targeted therapies in DLBCL

  • Recommend the optimal targeted treatment for each patient with DLBCL, considering subtype, comorbidities, expert recommendations, and available evidence

  • Identify patients with DLBCL who are eligible for clinical trials evaluating novel targeted therapies

Financial Disclosures

Primary Author

Elizabeth Budde, MD, PhD: consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, Crispr, Genentech/Roche; researcher: AstraZeneca, Merck.

Gilles Salles, MD, PhD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, BeOne, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, Genmab, GSK, Incyte, Ipsen, Janssen, Kite/Gilead, Lilly, Merck, Novartis; researcher (paid to institution): AbbVie, Daiichi Sankyo, Genentech, Genmab, Ipsen, Janssen.

Pier Luigi Zinzani, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeOne, Bristol Myers Squibb, Daichii Sankyo, Incyte, Janssen, Kite, Kyowa Kirin, Merck Sharp & Dohme, Novartis, Nurix, Roche, Sobi, Takeda.